Bangladesh Makes 98 Percent of Its Own Medicine — and Exports to 160 Countries

Bangladesh's pharmaceutical industry meets 98% of domestic demand and exports to over 160 countries including the US and EU. LDC graduation in November 2026 changes the rules.

Pharmaceutical packaging. Bangladesh's industry meets about 98 percent of domestic medicine demand. Photo: Aditiaudi, via Wikimedia Commons (CC BY-SA 4.0)

By the UISC BD Editorial Desk · United Information Service Center · Published 9 September 2026 · 7-minute read

Of all Bangladesh's industrial achievements, the pharmaceutical sector is the one that most consistently surprises people who encounter it for the first time. The country's roughly 213 active manufacturers supply about 98 percent of national medicine demand, and export to more than 160 countries — including the United States, several European nations, and Australia.

Those last three matter more than the headline count. Exporting medicine to the US and EU means passing FDA and EU-GMP inspections, a regulatory bar most developing-country manufacturers never clear.

From Import Dependence to Export Capacity

Bangladesh once imported the overwhelming majority of its medicines. The reversal was driven by a deliberate policy framework — the National Drug Policy of 1982 restricted imports of drugs that could be produced locally, giving domestic manufacturers a protected space to develop capability in.

Whatever one thinks of infant-industry protection in general, in this case it produced a sector that now competes internationally on quality rather than on shelter. In the first ten months of FY2024-25, pharmaceutical exports rose 3.46 percent year-on-year to $177.42 million.

Why It Matters Beyond the Balance Sheet

A country that manufactures its own medicines has a fundamentally different health-security position from one that imports them. Domestic production means supply is not hostage to foreign currency availability, shipping disruption, or export restrictions imposed by other governments during a crisis — a lesson many countries learned expensively during the COVID-19 pandemic.

It also means price. Locally produced generics cost a fraction of imported branded equivalents, which is the difference between a treatable condition being treated or not for a large share of the population. That connects directly to the country's recent WHO recognition on maternal mortality — affordable, available medicine is part of the infrastructure behind outcomes like that one.

The Deadline Arriving in November

Here is the part the industry has been preparing for and the coverage often understates. Bangladesh's graduation from Least Developed Country status is scheduled for November 2026 — weeks away at the time of writing.

LDC status carries a specific pharmaceutical benefit: a waiver under the WTO's TRIPS agreement allowing least-developed countries to manufacture patented medicines as generics without paying for licences. That waiver is the legal foundation on which a substantial share of Bangladesh's generic industry was built.

Graduation removes it. After November, producing a still-patented drug requires a licence like anyone else.

What the Industry Has To Do About It

The transition path the sector's own analysts describe involves moving up the value chain rather than defending the old position:

API industrialisation — producing active pharmaceutical ingredients domestically instead of importing them, capturing more of the value and reducing input dependence
Biosimilars and biologics — considerably more technically demanding than small-molecule generics, and correspondingly more valuable
More FDA and EU-GMP compliant facilities — the entry ticket to the highest-value regulated markets
Licensing arrangements with originator companies in place of the waiver

Industry projections suggest exports could pass $1 billion by 2029-30 if that transition is executed. That figure should be read as a target conditional on hard work being done, not a forecast.

The Honest Assessment

Bangladesh's pharmaceutical sector is the clearest existing proof that the country can build a technically sophisticated, globally competitive industry rather than only a labour-cost-competitive one. It is the template that the ICT sector's growth ambitions are implicitly modelled on.

It is also about to lose a structural advantage it has had since its founding. How the industry looks in 2030 will say a great deal about whether Bangladeshi manufacturing can move up a value chain when the protective conditions are withdrawn — which is, ultimately, the same question LDC graduation poses to the entire economy.

Sources

"Bangladesh's pharma industry moves from import dependence to global prominence," The Business Standard — tbsnews.net
"Pharmaceutical Industry in Bangladesh: Upholding Global Standards, Expanding Global Reach," IDLC Monthly Business Review — mbr.idlc.com
"Bangladesh Pharmaceutical & API Industry," Bangladesh Investment Development Authority — investbangladesh.gov.bd
"The rise and impact of Bangladesh's pharmaceutical industry," DHL — dhl.com

beximco square pharmaceuticals (1)

Bangladesh Makes 98% of Its Own Medicine — and Exports to 160 Countries